Typhoid fever vaccines are recombinant vaccines that provide protection against typhoid fever caused by Salmonella enterica serovar Typhi bacteria. Typhoid fever is a systemic infection that spreads through the blood and affects multiple organs. Symptoms include sustained high fever, weakness, stomach pain, headache, loss of appetite, and constipation or diarrhea. Typhoid fever can be life-threatening if not treated promptly. The global demand for typhoid fever vaccines is driven by rising awareness among people regarding vaccination, increasing government support for vaccination programs, and growing incidence of typhoid fever across both developed and developing countries.
The Global Typhoid Fever Vaccines Market is estimated to be valued at US$ 454.2 Bn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the typhoid fever vaccines are Linde Plc, Air Liquide, Engie, Uniper Se, Air Products Inc, Clean Hydrogen System, Cummins Inc., Toshiba Energy Systems & Solutions Corporation, Nel Asa, and Sgh2 Energy. Governments across many developing countries have initiated programs to vaccinate populations at risk. This factor is fueling demand for typhoid vaccines. With technological advancements, companies are developing more efficacious vaccine formulations which are driving the market.
Growing demand: Increasing funding for typhoid vaccination programs in schools and healthcare settings across Asia and Africa is a key factor boosting the uptake of typhoid vaccines. Governments are focusing on establishing mandatory vaccination routines which will propel the growth of this market over the forecast period.
Technological advancements: Companies are investing in research and development to develop improved typhoid vaccine formulations with high efficacy, long-lasting protection and easy administering capabilities. Recent advancements include WHO prequalification of Bharat Biotech's Typbar-TCV vaccine and launch of Vi-DT from Sanofi Pasteur.
Market Trends
Combination vaccines: There is a growing demand for combination vaccines that protect against typhoid fever as well as other infections. For example, typhoid conjugate vaccine Typbar-TCV by Bharat Biotech protects against both typhoid and Vi polysaccharide typhoid vaccine. This reduces the administrative and logistic challenges associated with multiple vaccinations.
Focus on emerging economies: Key players are increasing their focus on providing affordable typhoid vaccines to emerging economies of Asia, Africa, and Latin America where the disease burden is highest. Support from global health organizations to include typhoid vaccines in national immunization programs of these regions will provide major growth opportunities.
Market Opportunities
The rising funding support from global health organizations for typhoid vaccination programs presents significant opportunity for manufacturers. Introduction of single-dose typhoid vaccines and vaccines with longer lasting protection offers lucrative avenues. Furthermore, partnerships between private players and governments for local vaccine production can help increase accessibility and uptake in developing markets.
COVID-19 Impact on Typhoid Fever Vaccines Market Growth
The outbreak of COVID-19 pandemic has severely impacted the growth of typhoid fever vaccines market globally. During the initial phases of pandemic, production and supply chain disruptions affected the availability of typhoid vaccines. However, with the resumption of manufacturing facilities and relaxation of lockdown restrictions, vaccine supply has improved. Despite this, demand for typhoid vaccines declined sharply in 2020 as vaccination programs and routine immunization drives were stalled or postponed in several countries to prioritize COVID-19 vaccination efforts. Additionally, movement restrictions and fear of infection deterred people from visiting healthcare centers for typhoid immunization. These factors negatively impacted the market growth during the peak of pandemic. However, with measures in place to control COVID spread and promotion of routine vaccination by healthcare organizations, demand for typhoid vaccines is gradually recovering. Market players are scaling up vaccine production capacity and expanding distribution channels to cater growing needs. The long term outlook remains positive as efforts to contain typhoid and ensure universal immunization gain momentum in the post pandemic period.
Typhoid Fever Vaccines Market Growth Growth by Geographical Regions
In terms of value, Asia Pacific region holds the largest share of typhoid fever vaccines market currently. Countries like India, Pakistan and others report high typhoid incidence rates which is the key driver of vaccine demand in the region. Within Asia Pacific, India represents the fastest growing regional market. Latin America and Africa also present lucrative growth opportunities due to rising awareness, economic development and expansion of national immunization programs. North America and Europe are relatively mature markets though continuous medical innovation and adoption of newer typhoid vaccine formulations can drive incremental growth in these regions over the forecast period. Overall, developing regions with poor sanitation and weak public healthcare infrastructure will continue fueling the global expansion of typhoid fever vaccines market in the long run.
For more insights, read-https://www.newsstatix.com/typhoid-fever-vaccines-market-trends-size-and-share-analysis/
Unani medicine or herbal medicine may be a very ancient art of healing.
Antibiotics developed resistivity against many pathogens thanks to misuse of those agent that’s why antimicrobial potential is studied everywhere the planet .
